PDS Biotechnology Corp.
(NASDAQ : PDSB)

( )
PDSB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.74%178.190.7%$1350.94m
MRKMerck & Co., Inc. 0.21%92.610.7%$1211.55m
PFEPfizer Inc. -1.20%51.680.9%$1096.02m
LLYEli Lilly & Co. 0.74%327.131.1%$1026.00m
BMYBristol-Myers Squibb Co. -1.13%75.971.0%$991.64m
ABBVAbbVie, Inc. 0.03%153.851.9%$959.73m
AZNAstraZeneca Plc -0.67%65.511.0%$470.96m
SGENSeagen Inc. -1.85%176.775.7%$326.06m
GSKGSK Plc -1.01%43.310.2%$272.45m
TPTXTurning Point Therapeutics, Inc. 0.05%75.150.0%$199.28m
HZNPHorizon Therapeutics Plc 2.38%82.765.4%$174.09m
NVSNovartis AG -0.11%84.270.2%$172.25m
MRTXMirati Therapeutics, Inc. 1.10%71.961.6%$150.81m
ALNYAlnylam Pharmaceuticals, Inc. 1.67%150.738.1%$150.31m
NVONovo Nordisk A/S -0.40%111.190.1%$148.30m

Company Profile

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.